UK markets close in 1 hour 12 minutes

Shield Therapeutics plc (STX.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
1.9220-0.1280 (-6.24%)
As of 02:49PM BST. Market open.
Currency in GBp

Valuation measures4

Market cap (intra-day) 16.03M
Enterprise value 20.97M
Trailing P/E 53.33
Forward P/E 65.36
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.44
Price/book (mrq)1.36
Enterprise value/revenue 2.04
Enterprise value/EBITDA -1.49

Trading information

Stock price history

Beta (5Y monthly) 1.10
52-week change 3-69.40%
S&P500 52-week change 323.76%
52-week high 312.8500
52-week low 31.0630
50-day moving average 31.7761
200-day moving average 34.9719

Share statistics

Avg vol (3-month) 34.19M
Avg vol (10-day) 31.73M
Shares outstanding 5782.06M
Implied shares outstanding 6782.06M
Float 8410.13M
% held by insiders 156.18%
% held by institutions 115.81%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023


Profit margin -254.44%
Operating margin (ttm)-226.15%

Management effectiveness

Return on assets (ttm)-51.93%
Return on equity (ttm)-308.60%

Income statement

Revenue (ttm)13.09M
Revenue per share (ttm)0.02
Quarterly revenue growth (yoy)203.30%
Gross profit (ttm)N/A
EBITDA -31.08M
Net income avi to common (ttm)-33.29M
Diluted EPS (ttm)-0.0400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)13.95M
Total cash per share (mrq)0.02
Total debt (mrq)20.25M
Total debt/equity (mrq)134.67%
Current ratio (mrq)2.28
Book value per share (mrq)0.02

Cash flow statement

Operating cash flow (ttm)-37.13M
Levered free cash flow (ttm)-28.96M